Melissa L. Johnson
Sarah Cannon Research Institute(GB)Sarah Cannon(US)Tennessee Oncology(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, Colorectal Cancer Treatments and Studies, Protein Tyrosine Phosphatases
Most-Cited Works
- → First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer(2018)3,394 cited
- → PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma(2018)1,358 cited
- → The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients(2019)1,248 cited
- → Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation(2022)908 cited
- → Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer(2020)816 cited
- → Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial(2017)644 cited